[HTML][HTML] COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA. 1 era
J Hedvat, NW Lange, DM Salerno… - American Journal of …, 2022 - Elsevier
Treatment outcomes associated with the use of novel COVID-19 therapeutics in solid organ
transplant recipients (SOTR) are not well described in the literature. The objective of this …
transplant recipients (SOTR) are not well described in the literature. The objective of this …
[HTML][HTML] Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
Therapeutic options against SARS-CoV-2 are underutilized. Two oral drugs, molnupiravir
and paxlovid (nirmatrelvir/ritonavir), have received emergency use authorization. Initial trials …
and paxlovid (nirmatrelvir/ritonavir), have received emergency use authorization. Initial trials …
[HTML][HTML] Nirmatrelvir/ritonavir and molnupiravir in the treatment of mild/moderate COVID-19: results of a real-life study
I Gentile, R Scotto, N Schiano Moriello, B Pinchera… - Vaccines, 2022 - mdpi.com
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider …
Objective While COVID-19 vaccination prevents severe infections, poor immunogenicity in
immunocompromised people threatens vaccine effectiveness. We analysed the clinical …
immunocompromised people threatens vaccine effectiveness. We analysed the clinical …
[HTML][HTML] A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19
The recently discovered coronavirus, known as SARS-CoV-2, is a highly contagious and
potentially lethal viral infection that was declared a pandemic by the World Health …
potentially lethal viral infection that was declared a pandemic by the World Health …
Incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir
Importance Some patients treated with nirmatrelvir-ritonavir have experienced rebound of
COVID-19 infections and symptoms; however, data are scarce on whether viral rebound …
COVID-19 infections and symptoms; however, data are scarce on whether viral rebound …
[HTML][HTML] Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial
Background Well tolerated antivirals administered early in the course of COVID-19 infection
when the viremia is highest could prevent progression to severe disease. Favipiravir inhibits …
when the viremia is highest could prevent progression to severe disease. Favipiravir inhibits …
[HTML][HTML] COVID-19 infection in children: diagnosis and management
F Zhu, JY Ang - Current infectious disease reports, 2022 - Springer
Abstract Purpose of Review Due to the rapidly changing landscape of COVID-19, the
purpose of this review is to provide a concise and updated summary of pediatric COVID-19 …
purpose of this review is to provide a concise and updated summary of pediatric COVID-19 …
Covid-19: What is the evidence for the antiviral molnupiravir?
A Extance - bmj, 2022 - bmj.com
Covid-19: What is the evidence for the antiviral molnupiravir? | The BMJ Skip to main content
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …
Analysis of all-cause hospitalization and death among nonhospitalized patients with type 2 diabetes and SARS-CoV-2 infection treated with molnupiravir or …
Importance Diabetes and COVID-19 are both global pandemics, and type 2 diabetes is a
common comorbidity in patients with acute COVID-19 and is proven to be a key determinant …
common comorbidity in patients with acute COVID-19 and is proven to be a key determinant …